Promise of nearly a year of life on targeted drug not reality for all liver cancer patients, study finds

The median survival for a group of Medicare patients on the drug sorafenib was three months, which was significantly lower than the median survival of nearly 11 months for patients treated with the drug during a phase III clinical trial, report researchers.